Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease.

Authors

C Greb Alexandra, Kim Sowon, Roney Andrew, Ting Peng-Sheng, N Limketkai Berkeley, Chen Po-Hung

Published in

Digestive diseases and sciences. Jul 05, 2026. Epub Jul 05, 2026.

Abstract

Patients with liver disease often experience nutritional insufficiency due to an interplay of metabolic disturbances and dietary alterations leading to decreased muscle mass and the development of protein-calorie malnutrition (PCM). This study aimed to evaluate the prevalence of PCM in patients with steatotic liver disease (alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD)) and their impacts on mortality and healthcare utilization.
We identified hospitalizations with ALD, MASLD, and PCM using International Classification of Diseases codes in the National Inpatient Sample from 2016 to 2020. Descriptive analyses compared hospitalizations with and without PCM. Multivariable linear models adjusting for confounders evaluated the association between PCM and inpatient mortality, length of stay (LOS), and total charges.
PCM was found to be significantly more prevalent among hospitalizations with ALD or MASLD than those with neither (ALD 175.5 versus 51.8; MASLD 149.0 vs. 50.7; neither: 49.3 per 1000 hospitalizations; p < 0.001). Among hospitalizations with ALD nor MASLD, PCM was significantly associated with higher mortality (ALD adjusted odds ratio [aOR] 1.61; 95% CI 1.55-1.66; MASLD aOR 1.89; 95% CI 1.84-1.93), LOS (ALD 3.78 more days; 95% CI 3.67-3.88; MASLD 5.65 more days; 95% CI 5.53-5.77), and total charges (ALD $45,013; 95% CI $42,549-$47,477; MASLD $74,502; 95% CI $71,214-$77,789).
We found a higher prevalence of PCM among individuals with ALD compared to those with MASLD nor neither condition. PCM was associated with increased mortality, LOS, and total charges in those with ALD and MASLD. Our findings underscore the importance of early identification and management of PCM in patients with steatotic liver disease to mitigate adverse outcomes and reduce healthcare utilization.

PMID:
42402069
Bibliographic data and abstract were imported from PubMed on 05 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.